Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Maj 2021

Planlagt Fastgjort Låst Flyttet Genmab
1.2k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • S Offline
    S Offline
    Sukkeralf
    wrote on sidst redigeret af
    #521

    Immatics

    1 Reply Last reply
    0
    • BulderB Offline
      BulderB Offline
      Bulder
      wrote on sidst redigeret af
      #522

      så for s.... da, NBI i lille plus

      1 Reply Last reply
      0
      • nohopeN Offline
        nohopeN Offline
        nohope
        wrote on sidst redigeret af
        #523

        Når man opgør dagens tab - og der er 7 cifre foran kommaet - så havde minus 0,6 % p.a. jo været billigt sluppet.

        1 Reply Last reply
        0
        • Helge_LarsenPI-redaktørH Offline
          Helge_LarsenPI-redaktørH Offline
          Helge_LarsenPI-redaktør
          wrote on sidst redigeret af
          #524

          Tirsdagens aktier: Inflationsfrygt tog humøret - Lundbeck til tops. https://www.proinvestor.com/investornyt/675004/tirsdagens-aktier-inflationsfrygt-tog-humoret-lundbeck-til-tops

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #525

            @Sukkeralf any thoughts on that Immatics news? (from looking at their pipeline this does not seem like one of the
            Genmab bispecifics?)

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #526

              genmab presents at BofA , May 11-13; anyone know at what day precise and if there is a playback?

              1 Reply Last reply
              0
              • Helge_LarsenPI-redaktørH Offline
                Helge_LarsenPI-redaktørH Offline
                Helge_LarsenPI-redaktør
                wrote on sidst redigeret af
                #527

                US Biotech viser overraskende styrke i negativt marked
                https://www.proinvestor.com/investornyt/675010/us-biotech-viser-overraskende-styrke-i-negativt-marked

                1 Reply Last reply
                0
                • B Offline
                  B Offline
                  bikube
                  wrote on sidst redigeret af
                  #528

                  Så er der indløst warrats igen. Mon ikke det er sidste gang med de billige fra for 10 år siden. De næste må kun vente i 7 år.

                  1 Reply Last reply
                  0
                  • Helge_LarsenPI-redaktørH Offline
                    Helge_LarsenPI-redaktørH Offline
                    Helge_LarsenPI-redaktør
                    wrote on sidst redigeret af
                    #529

                    God morgen. 🙂

                    1 Reply Last reply
                    0
                    • P Offline
                      P Offline
                      Plimsoller
                      wrote on sidst redigeret af
                      #530

                      God morgen 🙂

                      1 Reply Last reply
                      0
                      • T Offline
                        T Offline
                        transalp
                        wrote on sidst redigeret af
                        #531

                        Go morgen. Og go dag med Helge i mio klubben. 🙂

                        1 Reply Last reply
                        0
                        • Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktør
                          wrote on sidst redigeret af
                          #532

                          Video: Tæt på Scandion Oncology, Ascelia Pharma & Hansa.:
                          https://www.proinvestor.com/index.php?p=debat_1&postid=93476

                          1 Reply Last reply
                          0
                          • Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktør
                            wrote on sidst redigeret af
                            #533

                            Spørgsmål til Q&A på mandag er mere end velkommen. Jeg har kun 5 stk´s inde nu.

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #534

                              I assume this is MIM-8 / Novo Nordisk ? Orphan Designation
                              https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=814121

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #535

                                apparantly Talquetamab
                                also got orphan designation in March (Teclistamab already got it last year)

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #536

                                  EHA Late breaking Dara abstract - SUBCUTANEOUS DARATUMUMAB + CYCLOPHOSPHAMIDE, BORTEZOMIB, AND DEXAMETHASONE (CYBORD) IN PATIENTS WITH NEWLY DIAGNOSED LIGHT CHAIN (AL) AMYLOIDOSIS: PRIMARY RESULTS FROM THE PHASE 3 ANDROMEDA STUDY - https://library.ehaweb.org/eha/2020/eha25th/303396/efstathios.kastritis.subcutaneous.daratumumab.2B.cyclophosphamide.bortezomib.html?f=listing%3D1*browseby%3D4*sortby%3D2*media%3D3*ce_id%3D1766*search%3Ddaratumumab*marker%3D794

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #537

                                    lol, no that is still the one from last year , 2020

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #538

                                      EHA poster SUBCUTANEOUS EPCORITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA: SAFETY PROFILE AND ANTI-TUMOR ACTIVITY https://library.ehaweb.org/eha/2021/eha2021-virtual-congress/325259/rogier.mous.subcutaneous.epcoritamab.in.patients.with.relapsed.refractory.html?f=listing%3D0*browseby%3D8*sortby%3D1*search%3Depcoritamab

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #539

                                        DARATUMUMAB MAINTENANCE VS OBSERVATION, finaly - Conclusion
                                        CASSIOPEIA part 2 interim analysis showed a significantly longer PFS with daratumumab maintenance vs OBS in transplant-eligible patients with NDMM. https://library.ehaweb.org/eha/2021/eha2021-virtual-congress/324588/philippe.moreau.daratumumab.maintenance.vs.observation.in.patients.with.newly.html?f=listing%3D1*browseby%3D8*sortby%3D2*media%3D3*ce_id%3D2035*label%3D21988*ot_id%3D25572*search%3Ddaratumumab*marker%3D1285

                                        1 Reply Last reply
                                        0
                                        • BulderB Offline
                                          BulderB Offline
                                          Bulder
                                          wrote on sidst redigeret af
                                          #540

                                          thx E L. What do you think of epco? Efficacy looks similar to glofitamab, but AE looks better. Best in class?

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger